US pharma executives reveal their attitudes to the UK and Brexit

in Pharmaceutical Articles

What will Brexit mean for pharma companies on both sides of the Atlantic? Given the ‘special relationship’ between the US and UK – and the particular track record of collaboration in the pharma industry – many people within and beyond the industry are trying to assess what the future will now hold.

In order to try to determine this, life sciences expert Alacrita conducted a survey to gauge the views of C-suite biotech executives in the US.

The results, outlined in the infographic below, show what these influential figures think about the European market now – and what they think might change when it comes to clinical trials and establishing an HQ five to ten years after Brexit…

The Special Pharma Relationship
Provided by Alacrita

Leave a Reply

Your email address will not be published.

*

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Latest from Pharmaceutical Articles

Go to Top